Strs Ohio purchased a new position in shares of GTx, Inc. (NASDAQ:GTXI) during the 2nd quarter, Holdings Channel reports. The institutional investor purchased 10,700 shares of the biopharmaceutical company’s stock, valued at approximately $163,000.
A number of other institutional investors have also recently added to or reduced their stakes in GTXI. Rock Springs Capital Management LP purchased a new position in GTX during the first quarter worth about $6,284,000. Point72 Asset Management L.P. purchased a new position in GTX during the first quarter worth about $1,917,000. Federated Investors Inc. PA purchased a new position in GTX during the first quarter worth about $1,558,000. Millennium Management LLC boosted its holdings in GTX by 107.0% during the first quarter. Millennium Management LLC now owns 121,957 shares of the biopharmaceutical company’s stock worth $2,165,000 after purchasing an additional 63,051 shares during the last quarter. Finally, Pendal Group Ltd purchased a new position in GTX during the second quarter worth about $735,000. Institutional investors and hedge funds own 28.38% of the company’s stock.
GTXI opened at $24.12 on Friday. GTx, Inc. has a twelve month low of $7.47 and a twelve month high of $25.60.
GTXI has been the topic of a number of research analyst reports. BidaskClub cut shares of GTX from a “hold” rating to a “sell” rating in a research note on Saturday, June 30th. ValuEngine upgraded shares of GTX from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 22nd. Finally, Zacks Investment Research upgraded shares of GTX from a “sell” rating to a “hold” rating in a research note on Tuesday, July 17th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $37.50.
In other GTX news, VP Henry Patton Doggrell sold 7,351 shares of the business’s stock in a transaction dated Wednesday, June 20th. The shares were sold at an average price of $19.01, for a total value of $139,742.51. Following the transaction, the vice president now directly owns 43,630 shares in the company, valued at $829,406.30. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Diane C. Young sold 2,049 shares of the business’s stock in a transaction dated Monday, July 16th. The shares were sold at an average price of $14.70, for a total transaction of $30,120.30. The disclosure for this sale can be found here. Over the last quarter, insiders sold 18,679 shares of company stock worth $346,257. Corporate insiders own 41.20% of the company’s stock.
GTX Company Profile
GTx, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer.
Recommended Story: Risk Tolerance and Your Investment Decisions
Want to see what other hedge funds are holding GTXI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GTx, Inc. (NASDAQ:GTXI).
Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.